Earnings summaries and quarterly performance for Corvus Pharmaceuticals.
Executive leadership at Corvus Pharmaceuticals.
Board of directors at Corvus Pharmaceuticals.
Research analysts who have asked questions during Corvus Pharmaceuticals earnings calls.
Aydin Huseynov
Ladenburg Thalmann
4 questions for CRVS
Also covers: ARDX, CAPR, CLRB +3 more
Jeff Jones
Oppenheimer & Co. Inc.
4 questions for CRVS
Also covers: ABEO, CLRB, CMMB +8 more
Graig Suvannavejh
Mizuho Securities
3 questions for CRVS
Also covers: ADAP, ADVM, ALEC +11 more
LW
Li Wang Watsek
Cantor Fitzgerald
3 questions for CRVS
Also covers: AFMD, ALXO, ARVN +7 more
JS
Jiale Song
Jefferies Financial Group Inc.
2 questions for CRVS
Also covers: ACRS, CTMX, CVAC +12 more
XL
Xun Lee
H.C. Wainwright & Co., LLC
2 questions for CRVS
Also covers: ATEC, CTSO, EDAP +2 more
CS
Craig Suvanevej
Mizuho Securities USA LLC
1 question for CRVS
RS
Roger Song
Jefferies
1 question for CRVS
Also covers: AADI, AKBA, ALT +13 more
Recent press releases and 8-K filings for CRVS.
Corvus Pharmaceuticals Presents Final Phase 1/1b Data for Soquelitinib in T Cell Lymphoma
CRVS
New Projects/Investments
- Corvus Pharmaceuticals presented final data from its Phase 1/1b trial of soquelitinib in patients with T cell lymphoma at the 67th American Society of Hematology Annual Meeting & Exposition.
- In the 200 mg BID cohort (N=24) of relapsed/refractory PTCL patients, the trial demonstrated a median progression-free survival of 6.2 months and a median overall survival of 28.1 months.
- This cohort also showed objective responses in 9 of 24 patients, including 6 complete responses, with no dose-limiting toxicities or significant adverse events observed.
- The data supports the ongoing registration Phase 3 trial for soquelitinib in relapsed/refractory PTCL, with interim data anticipated in late 2026 and trial completion in 2027.
- Soquelitinib has received Orphan Drug Designation for T cell lymphoma and Fast Track designation for relapsed/refractory PTCL from the FDA.
Dec 8, 2025, 3:30 PM
Corvus Pharmaceuticals Provides Update on Soquelitinib Development and Financial Runway
CRVS
New Projects/Investments
Guidance Update
- Corvus Pharmaceuticals (CRVS) is a clinical-stage company focused on developing first-in-class immune modulators, with its lead program, soquelitinib, in a Phase III registrational trial for peripheral T-cell lymphoma (PTCL) and a Phase Ib/soon-to-be Phase II trial for moderate to severe atopic dermatitis (AD).
- In atopic dermatitis, soquelitinib has demonstrated a safe profile and statistical separation from placebo at 28 days in initial cohorts, with a potential for a prolonged effect.
- The company is advancing soquelitinib into a global Phase II study for AD, a 12-week trial with an expected data readout in 2027.
- Corvus identifies a significant commercial opportunity in AD, estimating each 1% market share to be worth $1 billion, and plans to initiate an asthma study in 2026.
- As of September 30, Corvus reported $65 million in cash, providing a financial runway through Q4 2026.
Nov 10, 2025, 1:30 PM
Corvus Pharmaceuticals Reports Q3 2025 Financials and Soquelitinib Clinical Progress
CRVS
Earnings
New Projects/Investments
Board Change
- Corvus Pharmaceuticals reported a net loss of $10.2 million for the Third Quarter 2025, compared to a net loss of $40.2 million for the same period in 2024. Research and development expenses for Q3 2025 totaled $8.5 million, an increase from $5.2 million in Q3 2024.
- As of September 30, 2025, Corvus had $65.7 million in cash, cash equivalents, and marketable securities, and expects this cash to fund operations into the Fourth Quarter of 2026.
- For soquelitinib, results from the Extension Cohort 4 of the Phase I atopic dermatitis trial are anticipated to be reported in January 2026, and the Phase II atopic dermatitis trial is on track to begin in early Q1 2026.
- Enrollment is ongoing for the registrational Phase III trial of soquelitinib in relapsed Peripheral T-cell Lymphoma (PTCL), with interim data expected in late 2026.
- David Moore was appointed to the Board of Directors in October.
Nov 4, 2025, 9:30 PM
Corvus Pharmaceuticals Provides Business Update and Reports Q3 2025 Financial Results
CRVS
Earnings
Guidance Update
New Projects/Investments
- Corvus Pharmaceuticals reported a net loss of $10.2 million for the third quarter ended September 30, 2025, compared to a net loss of $40.2 million for the same period in 2024.
- Research and development expenses for Q3 2025 were $8.5 million, an increase from $5.2 million in Q3 2024, primarily due to higher clinical trial and manufacturing costs for soquelitinib.
- As of September 30, 2025, the company held $65.7 million in cash, cash equivalents, and marketable securities, and expects this cash to fund operations into the fourth quarter of 2026.
- The company completed enrollment in extension cohort 4 of the soquelitinib atopic dermatitis Phase 1 clinical trial, with data anticipated in January 2026, and is on track to initiate a Phase 2 clinical trial in early Q1 2026.
- Enrollment continues in the registrational Phase 3 clinical trial of soquelitinib in relapsed/refractory peripheral T cell lymphoma (PTCL), and final Phase 1/1b results for T cell lymphoma will be presented at the American Society of Hematology Annual Meeting in December 2025.
Nov 4, 2025, 9:01 PM
CRVS Provides Update on Soquelitinib Development and Clinical Trials
CRVS
New Projects/Investments
- CRVS is advancing Soquelitinib, an ITK inhibitor, with a randomized Phase 3 trial currently enrolling for Peripheral T-cell Lymphoma (PTCL), which could be the first fully FDA-approved drug for PTCL.
- In a Phase 1 study for moderate to severe Atopic Dermatitis (AD), Soquelitinib demonstrated favorable safety and tolerability, with Cohort 3 showing a mean EASI reduction of 64.8% and 25% of patients achieving IGA 0 or 1 at 4 weeks.
- Soquelitinib also showed clinically meaningful reductions in patient-reported pruritus (itch), with 50% of evaluable patients in Cohort 3 achieving a ≥4-point decrease in PP-NRS at Day 28.
- Key upcoming milestones include Phase 1 extension cohort 4 data for Atopic Dermatitis in January 2026 and Phase 2 trial initiation in early Q1 2026.
Nov 4, 2025, 9:00 PM
Corvus Pharmaceuticals Presents Interim Phase 1b/2 Clinical Trial Data for Ciforadenant in Metastatic RCC
CRVS
New Projects/Investments
- Corvus Pharmaceuticals (CRVS) announced the presentation of interim data from its Phase 1b/2 clinical trial of ciforadenant for metastatic renal cell cancer (RCC) at the European Society for Medical Oncology (ESMO) Congress 2025 on October 17, 2025.
- The triplet therapy, combining ciforadenant with ipilimumab and nivolumab, was found to be feasible and well tolerated in patients with unfavorable disease characteristics.
- As of May 2025, the trial demonstrated a deep response rate of 34%, an objective response rate (ORR) of 46% (including two complete responses and 21 partial responses), and a median progression-free survival (PFS) of 11.04 months.
- The 34% deep response rate shows an improvement compared to historical data of 32% for the doublet therapy alone, though it is not yet statistically significant.
- Nineteen patients remain on therapy for longer follow-up to further assess the potential benefits of blocking adenosine signaling with ciforadenant.
Oct 17, 2025, 2:00 PM
Corvus Pharmaceuticals Provides Pipeline Update at Oppenheimer Healthcare Conference
CRVS
New Projects/Investments
Guidance Update
- Corvus Pharmaceuticals' lead program, Socalitinib, is in a Phase 3 registrational trial for peripheral T cell lymphoma (PTCL) with data expected by mid-2026, and a Phase 1 trial for atopic dermatitis (AD), for which full data readout was expected in Q2 2025.
- A solid tumor study in renal cell carcinoma (RCC) was planned to start in Q2 2025, with data anticipated in H1 2026. Additionally, a Phase 2 trial for autoimmune lymphoproliferative syndrome (ALPS) was planned to start in March 2025, and initiation of a Phase 2 AD trial was planned for the second half of 2025.
- Preliminary efficacy data from the Phase 1 AD trial (cohorts 1 and 2) showed a 69% mean EASI reduction for the active arm at eight weeks, compared to 19% for placebo, and zero placebo responses in IgA 0,1 and EASI 75 endpoints, alongside a very attractive safety and tolerability profile.
- Corvus is also developing next-generation ITK inhibitors, which are approximately 12 to 15 months from entering the clinic.
Feb 11, 2025, 2:20 PM
Quarterly earnings call transcripts for Corvus Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more